There has been an impressive, little understood increase in cases of Autism Spectrum Disorders (ASD). The lack of any distinctive pathogenetic mechanism has hampered the development of any effective treatments. Increasing evidence indicates oxidative stress, brain inflammation, gastrointestinal (GI) dysfunction and allergic symptoms may be present in ASD patients. The flavone luteolin has antioxidant, anti-flammatory, anti-allergy and neuroprotective properties. Given these findings, a dietary supplement was developed with a unique mixture of luteolin with the related flavonoids quercetin and rutin in a liposomal formulation of olive kernel oil (OKO), which increases their absorption. Results are presented for children with ASD (n=37, 4-14 years old) who had not obtained any benefit from multiple other regimens and who used this formulation for at least 4 months. GI and allergy symptoms improved in about 75% of children, eye contact and attention in 50%, social interaction in 25% and resumption of speech in about 10%. There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness.
Autism Spectrum Disorders (ASD) are pervasive developmehtal disorders, diagnosed in early childhood (l) that have increased more than 10fold during the last decade to approximately 1/100 live births (2) . They are characterized by varying degrees of defective communication and social skills, cognitive, learning and sensory defects, as well as repetitive and stereotypic behaviors (l, 2) . The lack of any definitive pathogenesis has prevented the development of effective treatments for the core symptoms ofASD (3,4). In fact, recent studies have shown that use of selective serotonin reuptake inhibitor (SSRI) antidepressants (5) and some antipsychotics (6) may actually worsen ASD symptoms and cause the onset of adverse effects (7) . Consequently there is a great need for novel approaches to address ASD. chemokines, and cytokines, such as IL-6, IL-8, and TNF (9) . Mast cells are the only immune cells that store preformed TNF (11) . Neuro-immunoendocrine activation of mast cells in animal models can lead to disruption of both the gut-blood and blood-brain barriers (BBB) (12) . It is of particular importance that mast cells are also activated by neuropeptides often secreted during stress, such as neurotensin (9) , which has been shown to be elevated in the serum of young children with autism (13) . Acute stress increased serum IL-6 levels, a response that was entirely dependent on mast cells (14) .
Brain inflammation in ASD
Increasing evidence indicates that there is some immune dysfunction in ASD (15) . Postmortem brains of ASD patients had evidence of microglial activation and inflammation (16) . CSF levels ofTNF were significantly increased in autistic children (17) , while brains ofASD patients had elevated expression of IL-6 (18). Maternal viral infection or viral poly (I:C) injection in pregnant mice increased circulating IL-6 levels that crossed the placenta at midgestation and contributed to fetal brain injury and autistic-like behavior (19) .
Numerous reports from patients and recent studies indicate the presence of "allergic-like" symptoms in children with ASD (20) (21) (22) , implying mast cell activation. A preliminary retrospective study also reported much higher prevalence of ASD (1/10 children) in mastocytosis patients characterized by more and activated mast cells, than the general population (1/100 children) (23) . It is interesting that mastocytosis severity was shown to correlate with increased serum levels ofIL-6 (24).
Effect offlavonoids
Some naturally occurring flavonoids have potent anti-oxidant, and anti-inflammatory activities (25) . They can also inhibit histamine, IL-6, IL-8, TNF, and tryptase release from human mast cells (26) . In view of the fact that ASD has been associated with oxidative stress (27) , increased brain IL-6 expression and mast cell release of IL-6, especially in response to stress, we compared the ability of the flavone luteolin to that of its structurally-related flavone quercetin to inhibit IL-6 production from human cultured mast cells (Table I ). We report that flavonoids were best dissolved in olive kernel oil (OKO) and luteolin was more potent than quercetin inhibiting IL-6 release (Table I) .
Effects ofluteolin relevant to ASD
The beneficial actions of luteolin relevant to ASD are listed in Table II . Luteolin inhibits production of IL-6 from microglia (28) , and astrocytes (29) . Luteolin can also induce anti-inflammatory changes and neuroprotective changes in glial cells (30) . Luteolin also inhibits mast cell-dependent stimulation of activated T cells that participate in autoimmune diseases (31) and inhibits maternal IL-6-induced autism-like behavioral deficits in social interaction in mice (32) . Luteolin also blocks mercury-induced cytokine release from human mast cells (33) . Luteolin, and its structurally related, quercetin, inhibit histamine, leukotrienes and prostaglandin D 2 release from human cultured mast cells (34) . Quercetin also protected against swimming stress-induced increase in serum lipid hydroperoxide levels in rats (35) , and reversed acute stress-induced autistic-like behavior and low brain glutathione levels in mice (36) .
Neurol'rotek"
We designed a dietary flavonoid formulation to address the pathologic processes apparently present in ASD described above. This formulation (N eurol'rotek") is made by a Good Manufacturing Practices (GMP)-certified facility under contract from Algonot, LLC (www.algonot.com). Neurof'rotek" has a "Certificate of Free Export" from the Food and Drug Administration (FDA). Neurol'rotek" contains mainly luteolin (100 mg, from chamomile >95% pure), quercetin (70 mg, from Saphora, >95% pure), which will inhibit mast cell and act as "decoy" allowing more luteolin to escape metabolism and reach the brain, and the quercetin glycoside rutin (30 mg, from Saphora, >95% pure), which gets cleaved by intestinal bacteria and will reduce gut inflammation. Unfortunately, flavonoids are poorly absorbed after oral administration and Table III . Apparent benefits ofNeuroprotek" in ASD*.
Symptoms
Approximate improvement of children Fig. 1 . Diagrammatic representation ofthe sites ofbeneficial action oftheflavonoids in Neurol'rotek". Rutin will be generated and act primarily in the gut and reduce gut-inflammation and gut-blood barrier disrupt ion. Quercetin will act in all tissues and mostly in the skin to reduce "allergic-like " reactions, while luteolin will reduce brain inflammation and BBB permeability. undergo significant liver metabolism (37) limiting their systemic availability. Increased absorption of luteolin and quercetin is achieved by formulation in microspheres (liposomes) by mixing in OKO of low oleic acid and water content « 0.1%).
Each soft gel capsule contains 200 mg total flavonoid. We recommended at least 2 capsules/20 kg weight, or at least 400 mg total flavonoid. However, we may be underdosing. For instance, luteolin at 10 11M (necessary for 80% mast cell inhibition) is 3 mg per 1 liter= 1 kg, or 60 mg per 20 kg body weight. If we were to assume that our body is one compartment with equal distribution and maximal 10% absorption of luteolin, we should be administering 10x60 mg=600 mg/20 kg body weight, or 3 capsules/20 kg.
Apparent beneficial effects ofNeurol'rotek"
Data were obtained from responses submitted by the parents of children with ASD (n=37, 4-14 years old, 29 boys and 8 girls) from throughout the USA (Table III) . On average, patients (75%) reported significant improvement in their bowel color, form and habits within 2-3 weeks. "Allergic-like" symptoms, especially in the skin, were also significantly reduced in most of the children. Eye contact and increased attention to directions improved in about 50% of patients. As many as 30-50% of patients showed significant improvement in retained learned tasks and social interactions. Surprisingly, about 10% of children started speaking words or sentences. There was no apparent improvement in hyperactivity or aggressiveness. In fact, in 1-2 children who were apparently "intolerant to phenols", hyperactivity may have increased temporarily and decreased when the dose was lowered after two weeks.
The apparent benifit of Neurof'rotek" could be through reduction of brain and gut inflammation and may do so through inhibition of different processes, many of which involve mast cells (Fig. 1 ).
CONCLUSION
The present results are encouraging, since they suggest that a liposomal formulation of luteolin and quercetin, which are safe (38, 39) , are well tolerated and can have a positive impact. It is not apparent which ASD children will be helped most and to what extent. The results presented here are obviously limited by the lack of any specific psychometric instruments and an independent assessment by an external evaluator. A clinical study using Neurol'rotek" with various behavioral and biomarker end points in ASD children is ongoing in Greece and will be reported in the Fall of 2012. Moreover, a new formulation with reduced phenol content is available. It would also be interesting to assess the effect ofNeurol'rotek" together with other anti-inflammatory, anti-allergic and neuro-protective drugs such as the newer antidepressants (40) . 
